Bio-Techne Corp. (TECH) NASDAQ
$64.18 (2.55) (-3.82%)
Market Cap: $10.30B
As of 04/16/24 12:03 PM EDT. Market open.
Bio-Techne Corp. (TECH)
NASDAQ
$64.18
(2.55) (-3.82%)
Market Cap: $10.30B
As of 04/16/24 12:03 PM EDT. Market open.
Add to Portfolio
bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical ... read more
bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide. read less
COMPANY PROFILE
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
CEO
Charles Kummeth
Full Time Employees
1,595
CEO Compensation (Base)
$957,000
CEO Compensation (Total)
$11.01M
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
CEO
Charles Kummeth
Full Time Employees
1,595
CEO Compensation (Base)
$957,000
CEO Compensation (Total)
$11.01M
Address
614 McKinley Pl NE, Minnesota, Minneapolis, 55413-2610.
PRICE CHART FOR BIO-TECHNE CORP
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$65.36
Previous Close
$66.73
Days Range
$65.10 - $67.41
52 week range
$51.53 - $89.37
Volume
439,268
Avg. Volume (30 days)
968,515
Market Cap
$10.30B
Dividend Yield
0.49%
P/E
45.95
Shares Outstanding
157,191,685
Open
$65.36
Previous Close
$66.73
Days Range
$65.10 - $67.41
52 week range
$51.53 - $89.37
Volume
439,268
Avg. Volume (30 days)
968,515
Market Cap
$10.30B
Dividend Yield
0.49%
P/E
45.95
Shares Outstanding
157,191,685
FINANCIAL STATEMENTS FOR BIO-TECHNE CORP
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR BIO-TECHNE CORP
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Bohnen Shane | SVP - General Counsel | Apr 03, 2024 | Option Exercise | $67.87 | 747 | 50,699 | 1,647 | Apr 05, 2024, 04:53 PM |
| Nusse Roeland | Director | Mar 07, 2024 | Sale | $76.98 | 10,400 | 800,627 | 43,097 | Mar 11, 2024, 04:04 PM |
| Geist William | PRESIDENT, PROTEIN SCIENCES | Feb 01, 2024 | Option Exercise | $68.54 | 1,111 | 76,148 | 7,759 | Feb 05, 2024, 06:36 PM |
| Hippel James | CFO | Dec 19, 2023 | Option Exercise | $77.42 | 32,966 | 2,552,228 | 71,884 | Dec 21, 2023, 04:06 PM |
| Hippel James | CFO | Dec 19, 2023 | Option Exercise | $31.26 | 47,289 | 1,478,254 | 104,850 | Dec 21, 2023, 04:06 PM |
| Nusse Roeland | Director | Aug 30, 2023 | Option Exercise | $22.40 | 32,000 | 716,800 | 60,811 | Sep 01, 2023, 04:06 PM |
| Nusse Roeland | Director | Aug 30, 2023 | Sale | $80.32 | 8,939 | 717,959 | 51,872 | Sep 01, 2023, 04:06 PM |
| Kelderman Kim | Pres. Diagnostics & Genom | Aug 24, 2023 | Option Exercise | $47.60 | 2,100 | 99,960 | 21,225 | Aug 28, 2023, 04:19 PM |
| Kummeth Charles R. | Chief Executive Officer | Aug 15, 2023 | Option Exercise | $84.61 | 8,675 | 733,992 | 1,278,269 | Aug 17, 2023, 04:14 PM |
| Kummeth Charles R. | Chief Executive Officer | Aug 05, 2023 | Option Exercise | $82.17 | 31,962 | 2,626,317 | 1,278,320 | Aug 08, 2023, 05:31 PM |
| Hippel James | CFO | Aug 05, 2023 | Option Exercise | $82.17 | 6,335 | 520,547 | 57,561 | Aug 08, 2023, 05:29 PM |
| Kelderman Kim | Pres. Diagnostics & Genom | Aug 05, 2023 | Option Exercise | $82.17 | 4,139 | 340,102 | 19,125 | Aug 08, 2023, 05:28 PM |
| Kummeth Charles R. | Chief Executive Officer | Jul 21, 2023 | Sale | $88.36 | 80,000 | 7,069,024 | 1,258,766 | Jul 25, 2023, 05:27 PM |
| Kummeth Charles R. | Chief Executive Officer | Jun 30, 2023 | Option Exercise | $81.63 | 390,727 | 31,895,044 | 1,338,766 | Jul 05, 2023, 06:38 PM |
| Kummeth Charles R. | Chief Executive Officer | Jun 30, 2023 | Option Exercise | $26.65 | 616,676 | 16,434,415 | 1,729,493 | Jul 05, 2023, 06:38 PM |
| Kummeth Charles R. | Chief Executive Officer | Jun 07, 2023 | Sale | $83.00 | 322 | 26,726 | 1,112,817 | Jun 09, 2023, 04:07 PM |
| HIGGINS JOHN L | Director | Apr 28, 2023 | Option Exercise | $79.88 | 4,377 | 349,635 | 34,983 | May 02, 2023, 04:49 PM |
| HIGGINS JOHN L | Director | Apr 28, 2023 | Option Exercise | $21.85 | 16,000 | 349,600 | 39,360 | May 02, 2023, 04:49 PM |
| Kummeth Charles R. | Chief Executive Officer | Jan 04, 2023 | Option Exercise | $84.39 | 255,837 | 21,590,084 | 1,113,139 | Jan 06, 2023, 04:37 PM |
| Kummeth Charles R. | Chief Executive Officer | Jan 04, 2023 | Option Exercise | $26.65 | 407,364 | 10,856,250 | 1,368,976 | Jan 06, 2023, 04:37 PM |
| Furlow Brenda S. | SVP - GENERAL COUNSEL | Dec 08, 2022 | Option Exercise | $31.26 | 7,450 | 232,906 | 33,542 | Dec 09, 2022, 04:48 PM |
| Furlow Brenda S. | SVP - GENERAL COUNSEL | Dec 07, 2022 | Option Exercise | $31.26 | 800 | 25,010 | 26,892 | Dec 09, 2022, 04:48 PM |
| Furlow Brenda S. | SVP - GENERAL COUNSEL | Dec 07, 2022 | Sale | $82.01 | 800 | 65,605 | 26,092 | Dec 09, 2022, 04:48 PM |
| Furlow Brenda S. | SVP - GENERAL COUNSEL | Dec 08, 2022 | Sale | $82.12 | 7,450 | 611,810 | 26,092 | Dec 09, 2022, 04:48 PM |
| Kelderman Kim | Pres. Diagnostics & Genom | Aug 23, 2022 | Option Exercise | $150.78 | 663 | 99,967 | 3,801 | Aug 25, 2022, 05:38 PM |
| HIGGINS JOHN L | Director | Aug 10, 2022 | Option Exercise | $66.90 | 3,400 | 227,460 | 8,006 | Aug 12, 2022, 04:02 PM |
| HIGGINS JOHN L | Director | Aug 11, 2022 | Sale | $385.39 | 512 | 197,322 | 5,510 | Aug 12, 2022, 04:02 PM |
| HIGGINS JOHN L | Director | Aug 10, 2022 | Sale | $377.11 | 1,992 | 751,194 | 7,106 | Aug 12, 2022, 04:02 PM |
| Furlow Brenda S. | SVP - General Counsel | Aug 08, 2022 | Option Exercise | $177.32 | 563 | 99,831 | 6,523 | Aug 10, 2022, 06:08 PM |
| Kelderman Kim | Pres. Diagnostics & Genom | Aug 07, 2022 | Option Exercise | $382.97 | 1,214 | 464,926 | 3,138 | Aug 09, 2022, 07:00 PM |
| Furlow Brenda S. | SVP - General Counsel | Aug 07, 2022 | Option Exercise | $382.97 | 969 | 371,098 | 5,960 | Aug 09, 2022, 06:59 PM |
| Kummeth Charles R. | Chief Executive Officer | Aug 07, 2022 | Option Exercise | $382.97 | 11,557 | 4,425,984 | 240,403 | Aug 09, 2022, 06:58 PM |
| Hippel James | Chief Financial Officer | Aug 07, 2022 | Option Exercise | $382.97 | 1,938 | 742,196 | 12,755 | Aug 09, 2022, 06:57 PM |
| Kummeth Charles R. | CHIEF EXECUTIVE OFFICER | Jul 28, 2022 | Option Exercise | $380.76 | 27,707 | 10,549,718 | 235,042 | Aug 01, 2022, 06:11 PM |
| Kummeth Charles R. | CHIEF EXECUTIVE OFFICER | Jul 28, 2022 | Option Exercise | $108.49 | 45,346 | 4,919,587 | 262,749 | Aug 01, 2022, 06:11 PM |
| Kummeth Charles R. | CHIEF EXECUTIVE OFFICER | Jul 06, 2022 | Option Exercise | $362.78 | 30,935 | 11,222,599 | 217,403 | Jul 08, 2022, 05:18 PM |
| Kummeth Charles R. | CHIEF EXECUTIVE OFFICER | Jul 06, 2022 | Option Exercise | $108.49 | 50,000 | 5,424,500 | 248,338 | Jul 08, 2022, 05:18 PM |
| HIGGINS JOHN L | Director | Jun 08, 2022 | Option Exercise | $66.90 | 600 | 40,140 | 5,206 | Jun 09, 2022, 05:07 PM |
| HIGGINS JOHN L | Director | Jun 07, 2022 | Option Exercise | $66.90 | 1,000 | 66,900 | 5,606 | Jun 09, 2022, 05:07 PM |
| HIGGINS JOHN L | Director | Jun 08, 2022 | Sale | $366.09 | 600 | 219,654 | 4,606 | Jun 09, 2022, 05:07 PM |
| HIGGINS JOHN L | Director | Jun 07, 2022 | Sale | $364.31 | 1,000 | 364,310 | 4,606 | Jun 09, 2022, 05:07 PM |
| Kummeth Charles R. | CHIEF EXECUTIVE OFFICER | Jun 07, 2022 | Option Exercise | $108.49 | 5,104 | 553,733 | 203,442 | Jun 09, 2022, 05:05 PM |
| Kummeth Charles R. | CHIEF EXECUTIVE OFFICER | Jun 07, 2022 | Sale | $365.00 | 5,104 | 1,862,960 | 198,338 | Jun 09, 2022, 05:05 PM |
| BAUMGARTNER ROBERT V | Director | May 10, 2022 | Buy | $352.55 | 300 | 105,765 | 10,106 | May 11, 2022, 04:52 PM |
| Kelderman Kim | Pres. Diagnostics & Genom | Feb 08, 2022 | Option Exercise | $150.78 | 1,989 | 299,901 | 1,989 | Feb 10, 2022, 04:31 PM |
| Kummeth Charles R. | Chief Executive Officer | Jan 28, 2022 | Option Exercise | $115.08 | 1,737 | 199,896 | 198,338 | Feb 01, 2022, 04:35 PM |
| Kelderman Kim | Pres. Diagnostics & Genom | Nov 19, 2021 | Option Exercise | $150.78 | 500 | 75,390 | 500 | Nov 23, 2021, 08:02 PM |
| Kelderman Kim | Pres. Diagnostics & Genom | Nov 19, 2021 | Sale | $505.38 | 500 | 252,689 | 400 | Nov 23, 2021, 08:02 PM |
| Eansor Norman David | President-Protein Sciences | Nov 16, 2021 | Option Exercise | $125.05 | 799 | 99,915 | 2,117 | Nov 16, 2021, 04:51 PM |
| Eansor Norman David | President-Protein Sciences | Nov 12, 2021 | Option Exercise | $125.05 | 27,159 | 3,396,233 | 28,477 | Nov 16, 2021, 04:51 PM |
| Eansor Norman David | President-Protein Sciences | Nov 12, 2021 | Sale | $504.00 | 27,159 | 13,688,196 | 27,777 | Nov 16, 2021, 04:51 PM |
| Hippel James | Chief Financial Officer | Nov 01, 2021 | Option Exercise | $125.05 | 8,822 | 1,103,191 | 19,577 | Nov 03, 2021, 05:29 PM |
| Hippel James | Chief Financial Officer | Nov 02, 2021 | Option Exercise | $125.05 | 200 | 25,010 | 10,955 | Nov 03, 2021, 05:29 PM |
| Hippel James | Chief Financial Officer | Nov 02, 2021 | Sale | $525.10 | 200 | 105,020 | 10,755 | Nov 03, 2021, 05:29 PM |
| Hippel James | Chief Financial Officer | Nov 01, 2021 | Sale | $526.52 | 8,822 | 4,644,968 | 16,011 | Nov 03, 2021, 05:29 PM |
| Hippel James | Chief Financial Officer | Oct 29, 2021 | Option Exercise | $125.05 | 662 | 82,783 | 11,417 | Nov 01, 2021, 04:36 PM |
| Hippel James | Chief Financial Officer | Oct 29, 2021 | Sale | $525.23 | 662 | 347,704 | 10,755 | Nov 01, 2021, 04:36 PM |
| Hippel James | Chief Financial Officer | Oct 28, 2021 | Sale | $525.18 | 100 | 52,518 | 10,755 | Nov 01, 2021, 04:36 PM |
| Kelderman Kim | Pres. Diagnostics & Genom | Sep 22, 2021 | Sale | $529.04 | 822 | 434,871 | 0 | Sep 24, 2021, 04:30 PM |
| STEER RANDOLPH C | Director | Sep 07, 2021 | Option Exercise | $89.58 | 8,000 | 716,680 | 13,112 | Sep 09, 2021, 04:26 PM |
| STEER RANDOLPH C | Director | Sep 07, 2021 | Sale | $509.98 | 8,000 | 4,079,824 | 10,212 | Sep 09, 2021, 04:26 PM |
| Kummeth Charles R. | Chief Executive Officer | Sep 02, 2021 | Option Exercise | $510.78 | 42,005 | 21,455,314 | 196,601 | Sep 07, 2021, 05:00 PM |
| Kummeth Charles R. | Chief Executive Officer | Sep 02, 2021 | Option Exercise | $108.49 | 73,492 | 7,973,147 | 238,606 | Sep 07, 2021, 05:00 PM |
| Hippel James | Chief Financial Officer | Sep 02, 2021 | Option Exercise | $106.59 | 10,000 | 1,065,900 | 20,855 | Sep 07, 2021, 04:59 PM |
| Hippel James | Chief Financial Officer | Sep 02, 2021 | Sale | $507.22 | 10,000 | 5,072,164 | 10,862 | Sep 07, 2021, 04:59 PM |
| Furlow Brenda S. | SVP - General Counsel | Sep 02, 2021 | Option Exercise | $125.05 | 6,871 | 859,219 | 14,491 | Sep 07, 2021, 04:58 PM |
| Furlow Brenda S. | SVP - General Counsel | Sep 02, 2021 | Sale | $509.94 | 6,871 | 3,503,767 | 9,196 | Sep 07, 2021, 04:58 PM |
| Eansor Norman David | President-Protein Sciences | Aug 31, 2021 | Sale | $503.07 | 1,538 | 773,728 | 1,318 | Sep 02, 2021, 04:49 PM |
| Furlow Brenda S. | SVP - General Counsel | Aug 31, 2021 | Option Exercise | $125.05 | 5,000 | 625,250 | 12,620 | Sep 02, 2021, 04:48 PM |
| Furlow Brenda S. | SVP - General Counsel | Aug 31, 2021 | Sale | $505.66 | 5,000 | 2,528,312 | 12,297 | Sep 02, 2021, 04:48 PM |
| Nusse Roeland | Director | Aug 23, 2021 | Option Exercise | $70.35 | 4,000 | 281,400 | 10,765 | Aug 25, 2021, 05:13 PM |
| Nusse Roeland | Director | Aug 23, 2021 | Sale | $481.52 | 4,000 | 1,926,064 | 6,765 | Aug 25, 2021, 05:13 PM |
| BAUMGARTNER ROBERT V | Director | Aug 23, 2021 | Option Exercise | $87.39 | 4,000 | 349,560 | 13,612 | Aug 25, 2021, 04:42 PM |
| BAUMGARTNER ROBERT V | Director | Aug 23, 2021 | Sale | $485.55 | 4,000 | 1,942,184 | 13,313 | Aug 25, 2021, 04:42 PM |
| Furlow Brenda S. | SVP - General Counsel | Aug 19, 2021 | Option Exercise | $109.99 | 4,337 | 477,030 | 11,158 | Aug 23, 2021, 04:15 PM |
| Furlow Brenda S. | SVP - General Counsel | Aug 19, 2021 | Sale | $473.95 | 3,538 | 1,676,850 | 10,058 | Aug 23, 2021, 04:15 PM |
| Kummeth Charles R. | Chief Executive Officer | Aug 11, 2021 | Option Exercise | $108.49 | 921 | 99,919 | 165,114 | Aug 13, 2021, 04:03 PM |
| Kummeth Charles R. | Chief Executive Officer | Aug 06, 2021 | Option Exercise | $481.82 | 12,475 | 6,010,705 | 164,193 | Aug 10, 2021, 06:22 PM |
| Hippel James | Chief Financial Officer | Aug 08, 2021 | Option Exercise | $481.82 | 1,665 | 802,230 | 10,855 | Aug 10, 2021, 06:21 PM |
| Hippel James | Chief Financial Officer | Aug 09, 2021 | Option Exercise | $106.59 | 10,000 | 1,065,900 | 20,855 | Aug 10, 2021, 06:21 PM |
| Hippel James | Chief Financial Officer | Aug 09, 2021 | Sale | $478.90 | 10,000 | 4,788,994 | 15,655 | Aug 10, 2021, 06:21 PM |
| Kelderman Kim | Pres. Diagnostics & Genom | Aug 08, 2021 | Option Exercise | $481.82 | 869 | 418,702 | 822 | Aug 10, 2021, 06:21 PM |
| Furlow Brenda S. | SVP - General Counsel | Aug 08, 2021 | Option Exercise | $481.82 | 677 | 326,192 | 6,821 | Aug 10, 2021, 06:20 PM |
| Eansor Norman David | President-Protein Sciences | Aug 08, 2021 | Option Exercise | $481.82 | 999 | 481,338 | 2,856 | Aug 10, 2021, 06:19 PM |
| Hippel James | Chief Financial Officer | Jul 12, 2021 | Option Exercise | $106.59 | 10,000 | 1,065,900 | 19,137 | Jul 14, 2021, 04:57 PM |
| Hippel James | Chief Financial Officer | Jul 12, 2021 | Sale | $456.67 | 10,000 | 4,566,663 | 18,537 | Jul 14, 2021, 04:57 PM |
| Kelderman Kim | Pres. Diagnostics & Genom | May 01, 2021 | Option Exercise | $427.49 | 856 | 365,931 | 1,656 | May 04, 2021, 04:54 PM |
| Kummeth Charles R. | Chief Executive Officer | Feb 16, 2021 | Option Exercise | $411.00 | 17,428 | 7,162,908 | 158,841 | Feb 18, 2021, 12:00 AM |
| Kummeth Charles R. | Chief Executive Officer | Feb 16, 2021 | Option Exercise | $94.35 | 30,000 | 2,830,500 | 176,269 | Feb 18, 2021, 12:00 AM |
| Hippel James | Chief Financial Officer | Feb 12, 2021 | Option Exercise | $106.59 | 10,000 | 1,065,900 | 19,137 | Feb 17, 2021, 04:46 PM |
| Hippel James | Chief Financial Officer | Feb 12, 2021 | Sale | $400.39 | 10,000 | 4,003,909 | 9,737 | Feb 17, 2021, 04:46 PM |
| Furlow Brenda S. | SVP - General Counsel | Feb 12, 2021 | Option Exercise | $106.59 | 10,000 | 1,065,900 | 16,124 | Feb 17, 2021, 04:42 PM |
| Furlow Brenda S. | SVP - General Counsel | Feb 12, 2021 | Sale | $398.63 | 10,000 | 3,986,348 | 9,450 | Feb 17, 2021, 04:42 PM |
| Nusse Roeland | Director | Feb 08, 2021 | Option Exercise | $67.48 | 6,000 | 404,850 | 12,765 | Feb 10, 2021, 04:26 PM |
| Nusse Roeland | Director | Feb 08, 2021 | Sale | $385.08 | 6,000 | 2,310,480 | 6,765 | Feb 10, 2021, 04:26 PM |
| Kelderman Kim | Pres. Diagnostics & Genom | Feb 05, 2021 | Sale | $388.45 | 823 | 319,694 | 845 | Feb 09, 2021, 06:31 PM |
| Eansor Norman David | President-Protein Sciences | Feb 05, 2021 | Option Exercise | $106.59 | 32,933 | 3,510,328 | 34,251 | Feb 09, 2021, 05:24 PM |
| Eansor Norman David | President-Protein Sciences | Feb 05, 2021 | Sale | $380.68 | 32,933 | 12,537,024 | 28,251 | Feb 09, 2021, 05:24 PM |
| Kummeth Charles R. | Chief Executive Officer | Jan 15, 2021 | Sale | $344.00 | 20,000 | 6,880,000 | 146,269 | Jan 20, 2021, 04:42 PM |
| Hippel James | Chief Financial Officer | Jan 11, 2021 | Option Exercise | $106.59 | 10,000 | 1,065,900 | 19,137 | Jan 13, 2021, 05:18 PM |
| Hippel James | Chief Financial Officer | Jan 11, 2021 | Sale | $333.63 | 10,000 | 3,336,323 | 18,737 | Jan 13, 2021, 05:18 PM |
| Kummeth Charles R. | Chief Executive Officer | Dec 07, 2020 | Sale | $308.00 | 5,000 | 1,540,000 | 166,269 | Dec 09, 2020, 04:28 PM |
| Furlow Brenda S. | SVP - General Counsel | Nov 30, 2020 | Option Exercise | $106.59 | 11,795 | 1,257,229 | 16,981 | Dec 02, 2020, 06:01 PM |
| Furlow Brenda S. | SVP - General Counsel | Nov 30, 2020 | Sale | $301.94 | 10,857 | 3,278,128 | 13,614 | Dec 02, 2020, 06:01 PM |
| BAUMGARTNER ROBERT V | Director | Nov 18, 2020 | Option Exercise | $66.90 | 5,000 | 334,500 | 14,612 | Nov 20, 2020, 04:29 PM |
| BAUMGARTNER ROBERT V | Director | Nov 18, 2020 | Sale | $303.33 | 5,000 | 1,516,675 | 9,612 | Nov 20, 2020, 04:29 PM |
| Seth Alpna | Director | Nov 09, 2020 | Option Exercise | $145.75 | 5,023 | 732,118 | 7,162 | Nov 19, 2020, 12:27 PM |
| Seth Alpna | Director | Nov 09, 2020 | Sale | $306.62 | 5,023 | 1,540,167 | 5,804 | Nov 19, 2020, 12:27 PM |
| Hippel James | Chief Financial Officer | Nov 11, 2020 | Option Exercise | $106.59 | 7,391 | 787,807 | 16,528 | Nov 12, 2020, 06:59 PM |
| Hippel James | Chief Financial Officer | Nov 09, 2020 | Option Exercise | $106.59 | 3,600 | 383,724 | 12,737 | Nov 12, 2020, 06:59 PM |
| Hippel James | Chief Financial Officer | Nov 11, 2020 | Sale | $307.05 | 7,391 | 2,269,426 | 10,237 | Nov 12, 2020, 06:59 PM |
| Hippel James | Chief Financial Officer | Nov 09, 2020 | Sale | $309.79 | 3,600 | 1,115,252 | 11,637 | Nov 12, 2020, 06:59 PM |
| Kummeth Charles R. | Chief Executive Officer | Nov 06, 2020 | Option Exercise | $302.47 | 15,375 | 4,650,476 | 171,269 | Nov 10, 2020, 06:04 PM |
| Kummeth Charles R. | Chief Executive Officer | Nov 06, 2020 | Option Exercise | $86.25 | 25,157 | 2,169,791 | 186,644 | Nov 10, 2020, 06:04 PM |
| STEER RANDOLPH C | Director | Nov 06, 2020 | Option Exercise | $68.63 | 10,000 | 686,250 | 15,112 | Nov 10, 2020, 06:00 PM |
| STEER RANDOLPH C | Director | Nov 06, 2020 | Sale | $301.99 | 10,000 | 3,019,948 | 13,389 | Nov 10, 2020, 06:00 PM |
| HIGGINS JOHN L | Director | Nov 06, 2020 | Option Exercise | $70.35 | 5,000 | 351,750 | 9,412 | Nov 10, 2020, 04:53 PM |
| HIGGINS JOHN L | Director | Nov 06, 2020 | Sale | $300.35 | 5,000 | 1,501,746 | 7,962 | Nov 10, 2020, 04:53 PM |
| Hippel James | Chief Financial Officer | Nov 05, 2020 | Option Exercise | $108.49 | 8,809 | 955,688 | 17,946 | Nov 06, 2020, 04:47 PM |
| Hippel James | Chief Financial Officer | Nov 04, 2020 | Option Exercise | $108.49 | 7,100 | 770,279 | 16,237 | Nov 06, 2020, 04:47 PM |
| Hippel James | Chief Financial Officer | Nov 04, 2020 | Sale | $274.00 | 7,100 | 1,945,426 | 14,682 | Nov 06, 2020, 04:47 PM |
| Hippel James | Chief Financial Officer | Nov 05, 2020 | Sale | $286.12 | 8,809 | 2,520,454 | 17,548 | Nov 06, 2020, 04:47 PM |
| Furlow Brenda S. | SVP - General Counsel | Aug 09, 2020 | Option Exercise | $265.76 | 849 | 225,630 | 5,186 | Aug 11, 2020, 06:22 PM |
| Eansor Norman David | President-Protein Sciences | Aug 09, 2020 | Option Exercise | $265.76 | 856 | 227,491 | 1,318 | Aug 11, 2020, 06:21 PM |
| Hippel James | Chief Financial Officer | Aug 09, 2020 | Option Exercise | $265.76 | 2,184 | 580,420 | 9,137 | Aug 11, 2020, 06:21 PM |
| Kummeth Charles R. | Chief Executive Officer | Aug 09, 2020 | Option Exercise | $265.76 | 12,287 | 3,265,393 | 161,487 | Aug 11, 2020, 06:20 PM |
| Furlow Brenda S. | SVP - General Counsel | Jul 09, 2020 | Option Exercise | $108.49 | 9,079 | 984,981 | 13,390 | Jul 13, 2020, 04:02 PM |
| Furlow Brenda S. | SVP - General Counsel | Jul 09, 2020 | Sale | $275.76 | 9,079 | 2,503,654 | 12,950 | Jul 13, 2020, 04:02 PM |
| Hippel James | Chief Financial Officer | Jul 07, 2020 | Option Exercise | $108.49 | 2,577 | 279,579 | 11,884 | Jul 08, 2020, 05:47 PM |
| Hippel James | Chief Financial Officer | Jul 06, 2020 | Option Exercise | $108.49 | 21,502 | 2,332,752 | 30,809 | Jul 08, 2020, 05:47 PM |
| Hippel James | Chief Financial Officer | Jul 07, 2020 | Sale | $271.43 | 2,577 | 699,482 | 11,470 | Jul 08, 2020, 05:47 PM |
| Hippel James | Chief Financial Officer | Jul 06, 2020 | Sale | $271.61 | 21,502 | 5,840,148 | 21,238 | Jul 08, 2020, 05:47 PM |
| WIENS HAROLD J | Director | May 29, 2020 | Option Exercise | $101.19 | 3,985 | 403,242 | 8,828 | Jun 02, 2020, 05:13 PM |
| WIENS HAROLD J | Director | May 29, 2020 | Sale | $260.00 | 3,985 | 1,036,100 | 4,843 | Jun 02, 2020, 05:13 PM |
| Furlow Brenda S. | SVP - General Counsel | May 28, 2020 | Option Exercise | $105.51 | 7,595 | 801,358 | 10,306 | Jun 01, 2020, 05:58 PM |
| Furlow Brenda S. | SVP - General Counsel | May 28, 2020 | Sale | $260.14 | 5,995 | 1,559,534 | 8,111 | Jun 01, 2020, 05:58 PM |
| Eansor Norman David | President-Protein Sciences | May 29, 2020 | Option Exercise | $108.49 | 7,909 | 858,047 | 7,909 | Jun 01, 2020, 05:58 PM |
| Eansor Norman David | President-Protein Sciences | May 28, 2020 | Option Exercise | $108.49 | 3,448 | 374,074 | 3,448 | Jun 01, 2020, 05:58 PM |
| Eansor Norman David | President-Protein Sciences | May 29, 2020 | Sale | $262.00 | 7,909 | 2,072,140 | 6,209 | Jun 01, 2020, 05:58 PM |
| Eansor Norman David | President-Protein Sciences | May 28, 2020 | Sale | $260.19 | 3,448 | 897,135 | 0 | Jun 01, 2020, 05:58 PM |
| Kummeth Charles R. | Chief Executive Officer | May 26, 2020 | Option Exercise | $266.40 | 13,018 | 3,467,995 | 138,130 | May 28, 2020, 05:41 PM |
| Kummeth Charles R. | Chief Executive Officer | May 26, 2020 | Option Exercise | $86.25 | 21,159 | 1,824,964 | 151,148 | May 28, 2020, 05:41 PM |
| Eansor Norman David | President-Protein Sciences | May 22, 2020 | Option Exercise | $104.04 | 12,600 | 1,310,937 | 12,600 | May 26, 2020, 05:13 PM |
| Eansor Norman David | President-Protein Sciences | May 21, 2020 | Option Exercise | $94.35 | 11,037 | 1,041,341 | 11,037 | May 26, 2020, 05:13 PM |
| Eansor Norman David | President-Protein Sciences | May 22, 2020 | Sale | $267.93 | 12,600 | 3,375,926 | 4,924 | May 26, 2020, 05:13 PM |
| Eansor Norman David | President-Protein Sciences | May 21, 2020 | Sale | $267.49 | 11,037 | 2,952,316 | 900 | May 26, 2020, 05:13 PM |
| BAUMGARTNER ROBERT V | Director | May 21, 2020 | Option Exercise | $70.35 | 5,000 | 351,750 | 14,221 | May 26, 2020, 05:13 PM |
| BAUMGARTNER ROBERT V | Director | May 21, 2020 | Sale | $266.42 | 5,000 | 1,332,118 | 12,921 | May 26, 2020, 05:13 PM |
| WIENS HAROLD J | Director | May 06, 2020 | Option Exercise | $87.34 | 4,260 | 372,068 | 9,481 | May 08, 2020, 04:17 PM |
| WIENS HAROLD J | Director | May 06, 2020 | Sale | $250.00 | 4,260 | 1,065,000 | 5,221 | May 08, 2020, 04:17 PM |
| Kelderman Kim | Pres. Diagnostics & Genom | May 01, 2020 | Option Exercise | $227.54 | 821 | 186,810 | 1,668 | May 05, 2020, 04:28 PM |
| WIENS HAROLD J | Director | Apr 30, 2020 | Option Exercise | $91.78 | 4,000 | 367,120 | 9,221 | May 04, 2020, 04:35 PM |
| WIENS HAROLD J | Director | Apr 30, 2020 | Sale | $225.00 | 4,000 | 900,000 | 5,221 | May 04, 2020, 04:35 PM |
| Eansor Norman David | President-Protein Sciences | Mar 04, 2020 | Sale | $198.68 | 1,387 | 275,569 | 0 | Mar 06, 2020, 04:08 PM |
| HIGGINS JOHN L | Director | Feb 12, 2020 | Option Exercise | $61.46 | 5,000 | 307,300 | 9,021 | Feb 14, 2020, 04:13 PM |
| HIGGINS JOHN L | Director | Feb 12, 2020 | Sale | $205.23 | 5,000 | 1,026,135 | 4,021 | Feb 14, 2020, 04:13 PM |
| Kummeth Charles R. | Chief Executive Officer | Jan 06, 2020 | Option Exercise | $67.46 | 10,276 | 693,219 | 140,265 | Jan 08, 2020, 04:34 PM |
| Kummeth Charles R. | Chief Executive Officer | Jan 06, 2020 | Sale | $217.28 | 10,276 | 2,232,769 | 129,989 | Jan 08, 2020, 04:34 PM |
| Kummeth Charles R. | Chief Executive Officer | Jan 03, 2020 | Option Exercise | $67.46 | 7,999 | 539,613 | 137,988 | Jan 06, 2020, 12:00 AM |
| Kummeth Charles R. | Chief Executive Officer | Jan 02, 2020 | Option Exercise | $67.46 | 19,843 | 1,338,609 | 149,832 | Jan 06, 2020, 12:00 AM |
| Kummeth Charles R. | Chief Executive Officer | Jan 03, 2020 | Sale | $217.56 | 7,999 | 1,740,240 | 131,730 | Jan 06, 2020, 12:00 AM |
| Kummeth Charles R. | Chief Executive Officer | Jan 02, 2020 | Sale | $218.59 | 19,843 | 4,337,541 | 143,383 | Jan 06, 2020, 12:00 AM |
| Kummeth Charles R. | Chief Executive Officer | Dec 23, 2019 | Option Exercise | $67.46 | 659 | 44,456 | 130,648 | Dec 27, 2019, 04:31 PM |
| Kummeth Charles R. | Chief Executive Officer | Dec 24, 2019 | Option Exercise | $67.46 | 471 | 31,774 | 130,460 | Dec 27, 2019, 04:31 PM |
| Kummeth Charles R. | Chief Executive Officer | Dec 23, 2019 | Sale | $222.08 | 659 | 146,351 | 129,989 | Dec 27, 2019, 04:31 PM |
| Kummeth Charles R. | Chief Executive Officer | Dec 24, 2019 | Sale | $222.18 | 471 | 104,648 | 129,989 | Dec 27, 2019, 04:31 PM |
| Kummeth Charles R. | Chief Executive Officer | Dec 20, 2019 | Option Exercise | $67.46 | 5,767 | 389,042 | 135,756 | Dec 23, 2019, 04:32 PM |
| Kummeth Charles R. | Chief Executive Officer | Dec 20, 2019 | Sale | $222.06 | 5,767 | 1,280,632 | 129,989 | Dec 23, 2019, 04:32 PM |
| Kummeth Charles R. | Chief Executive Officer | Dec 20, 2019 | Option Exercise | $67.46 | 5,767 | 389,042 | 135,756 | Dec 23, 2019, 04:31 PM |
| Kummeth Charles R. | Chief Executive Officer | Dec 20, 2019 | Sale | $222.06 | 5,767 | 1,280,632 | 129,989 | Dec 23, 2019, 04:31 PM |
| Furlow Brenda S. | SVP - General Counsel | Dec 12, 2019 | Option Exercise | $94.35 | 8,000 | 754,800 | 10,711 | Dec 17, 2019, 04:32 PM |
| Furlow Brenda S. | SVP - General Counsel | Dec 12, 2019 | Sale | $215.60 | 8,000 | 1,724,773 | 10,285 | Dec 17, 2019, 04:32 PM |
| Kummeth Charles R. | Chief Executive Officer | Dec 10, 2019 | Option Exercise | $67.46 | 703 | 47,424 | 136,459 | Dec 12, 2019, 04:35 PM |
| Kummeth Charles R. | Chief Executive Officer | Dec 10, 2019 | Sale | $222.01 | 703 | 156,073 | 135,756 | Dec 12, 2019, 04:35 PM |
| WIENS HAROLD J | Director | Dec 04, 2019 | Option Exercise | $87.83 | 2,000 | 175,660 | 7,221 | Dec 06, 2019, 04:50 PM |
| WIENS HAROLD J | Director | Dec 04, 2019 | Sale | $217.85 | 2,000 | 435,693 | 6,736 | Dec 06, 2019, 04:50 PM |
| Kummeth Charles R. | Chief Executive Officer | Nov 27, 2019 | Option Exercise | $67.46 | 11,772 | 794,139 | 147,628 | Dec 02, 2019, 04:22 PM |
| Kummeth Charles R. | Chief Executive Officer | Nov 27, 2019 | Sale | $222.12 | 11,772 | 2,614,820 | 135,856 | Dec 02, 2019, 04:22 PM |
| Kummeth Charles R. | Chief Executive Officer | Nov 29, 2019 | Sale | $222.62 | 100 | 22,262 | 135,756 | Dec 02, 2019, 04:22 PM |
| Nusse Roeland | Director | Nov 25, 2019 | Option Exercise | $60.79 | 15,000 | 911,900 | 20,721 | Nov 29, 2019, 11:35 AM |
| Nusse Roeland | Director | Nov 25, 2019 | Sale | $219.33 | 8,347 | 1,830,731 | 12,374 | Nov 29, 2019, 11:35 AM |
| Hippel James | Chief Financial Officer | Nov 21, 2019 | Option Exercise | $94.35 | 11,349 | 1,070,778 | 20,656 | Nov 25, 2019, 04:25 PM |
| Hippel James | Chief Financial Officer | Nov 22, 2019 | Option Exercise | $94.35 | 23,651 | 2,231,472 | 32,958 | Nov 25, 2019, 04:25 PM |
| Hippel James | Chief Financial Officer | Nov 22, 2019 | Sale | $215.59 | 23,651 | 5,098,899 | 10,907 | Nov 25, 2019, 04:25 PM |
| Hippel James | Chief Financial Officer | Nov 21, 2019 | Sale | $215.36 | 11,349 | 2,444,132 | 9,307 | Nov 25, 2019, 04:25 PM |
| Kummeth Charles R. | Chief Executive Officer | Sep 09, 2019 | Buy | $185.00 | 100 | 18,500 | 100 | Sep 11, 2019, 04:42 PM |
| Kummeth Charles R. | Chief Executive Officer | Sep 09, 2019 | Buy | $185.00 | 100 | 18,500 | 100 | Sep 11, 2019, 04:42 PM |
| Eansor Norman David | SVP - Novus Biologicals | Aug 19, 2019 | Option Exercise | $197.57 | 900 | 177,813 | 1,387 | Aug 21, 2019, 04:34 PM |
| Hippel James | Chief Financial Officer | Aug 19, 2019 | Option Exercise | $197.57 | 2,424 | 478,910 | 6,883 | Aug 21, 2019, 04:33 PM |
| Furlow Brenda S. | SVP - General Counsel | Aug 19, 2019 | Option Exercise | $197.57 | 745 | 147,190 | 3,203 | Aug 21, 2019, 04:32 PM |
| Kummeth Charles R. | Chief Executive Officer | Aug 13, 2019 | Option Exercise | $67.46 | 7,410 | 499,879 | 110,877 | Aug 15, 2019, 04:45 PM |
| BAUMGARTNER ROBERT V | Director | Aug 07, 2019 | Buy | $191.06 | 500 | 95,530 | 8,726 | Aug 09, 2019, 04:12 PM |
| Kummeth Charles R. | Chief Executive Officer | Jul 10, 2019 | Option Exercise | $67.46 | 16,969 | 1,144,729 | 109,145 | Jul 12, 2019, 04:18 PM |
| Kummeth Charles R. | Chief Executive Officer | Jul 10, 2019 | Sale | $213.12 | 16,969 | 3,616,427 | 102,579 | Jul 12, 2019, 04:18 PM |
| Kummeth Charles R. | Chief Executive Officer | Jul 08, 2019 | Option Exercise | $67.46 | 17,994 | 1,213,875 | 110,170 | Jul 10, 2019, 04:46 PM |
| Kummeth Charles R. | Chief Executive Officer | Jul 09, 2019 | Option Exercise | $67.46 | 15,037 | 1,014,396 | 107,213 | Jul 10, 2019, 04:46 PM |
| Kummeth Charles R. | Chief Executive Officer | Jul 08, 2019 | Sale | $212.75 | 17,994 | 3,828,188 | 92,176 | Jul 10, 2019, 04:46 PM |
| Kummeth Charles R. | Chief Executive Officer | Jul 09, 2019 | Sale | $212.43 | 15,037 | 3,194,340 | 92,176 | Jul 10, 2019, 04:46 PM |
| Eansor Norman David | SVP - Novus Biologicals | Jun 12, 2019 | Sale | $215.00 | 3,117 | 670,155 | 0 | Jun 14, 2019, 04:13 PM |
| HIGGINS JOHN L | Director | Jun 04, 2019 | Option Exercise | $63.03 | 5,000 | 315,150 | 8,526 | Jun 06, 2019, 04:30 PM |
| HIGGINS JOHN L | Director | Jun 04, 2019 | Sale | $203.67 | 5,000 | 1,018,345 | 3,526 | Jun 06, 2019, 04:30 PM |
| Furlow Brenda S. | SVP - General Counsel | May 24, 2019 | Sale | $200.00 | 5,400 | 1,080,000 | 2,189 | May 29, 2019, 04:29 PM |
| Kelderman Kim | President, Diagnostics & Genom | May 01, 2019 | Option Exercise | $202.13 | 844 | 170,598 | 823 | May 02, 2019, 04:18 PM |
| Kelderman Kim | President, Diagnostics & Genom | May 01, 2019 | Option Exercise | $202.13 | 1,667 | 336,951 | 1,667 | May 02, 2019, 04:18 PM |
| Hippel James | Chief Financial Officer | May 01, 2019 | Option Exercise | $86.25 | 35,000 | 3,018,750 | 39,382 | May 02, 2019, 04:14 PM |
| Hippel James | Chief Financial Officer | May 01, 2019 | Sale | $203.08 | 35,000 | 7,107,695 | 4,382 | May 02, 2019, 04:14 PM |
| Kummeth Charles R. | Chief Executive Officer | Aug 18, 2018 | Option Exercise | $180.50 | 1,338 | 241,509 | 92,176 | Aug 31, 2018, 04:39 PM |
| BAUMGARTNER ROBERT V | Director | Aug 24, 2018 | Option Exercise | $61.46 | 5,000 | 307,300 | 12,712 | Aug 28, 2018, 05:30 PM |
| BAUMGARTNER ROBERT V | Director | Aug 24, 2018 | Sale | $188.47 | 5,000 | 942,335 | 7,712 | Aug 28, 2018, 05:30 PM |
| HIGGINS JOHN L | Director | Aug 23, 2018 | Option Exercise | $61.08 | 10,000 | 610,800 | 13,012 | Aug 27, 2018, 04:12 PM |
| HIGGINS JOHN L | Director | Aug 23, 2018 | Sale | $187.92 | 10,000 | 1,879,170 | 3,012 | Aug 27, 2018, 04:12 PM |
| Dinarello Charles A | Director | Aug 08, 2018 | Option Exercise | $63.03 | 5,000 | 315,150 | 13,212 | Aug 10, 2018, 04:18 PM |
| Dinarello Charles A | Director | Aug 08, 2018 | Sale | $176.93 | 5,000 | 884,675 | 8,212 | Aug 10, 2018, 04:18 PM |
| Kummeth Charles R. | Chief Executive Officer | Aug 07, 2018 | Option Exercise | $180.14 | 8,053 | 1,450,667 | 83,987 | Aug 09, 2018, 07:22 PM |
| Eansor Norman David | SVP - Novus Biologicals | Aug 07, 2018 | Option Exercise | $180.14 | 348 | 62,689 | 3,117 | Aug 09, 2018, 06:29 PM |
| Furlow Brenda S. | SVP - General Counsel | Aug 07, 2018 | Option Exercise | $180.14 | 438 | 78,901 | 2,189 | Aug 09, 2018, 06:26 PM |
| Hippel James | Chief Financial Officer | Aug 07, 2018 | Option Exercise | $180.14 | 1,094 | 197,073 | 4,382 | Aug 09, 2018, 06:19 PM |
| Kummeth Charles R. | Chief Executive Officer | Jun 07, 2018 | Sale | $160.00 | 8,000 | 1,280,000 | 76,472 | Jun 08, 2018, 04:21 PM |
| Eansor Norman David | SVP - Novus Biologicals | May 04, 2018 | Sale | $145.19 | 1,136 | 164,931 | 2,266 | May 11, 2018, 04:16 PM |
| Dinarello Charles A | Director | Feb 13, 2018 | Option Exercise | $65.47 | 5,000 | 327,350 | 13,212 | Feb 15, 2018, 04:02 PM |
| Dinarello Charles A | Director | Feb 13, 2018 | Sale | $136.06 | 5,000 | 680,303 | 10,717 | Feb 15, 2018, 04:02 PM |
| BAUMGARTNER ROBERT V | Director | Nov 01, 2017 | Option Exercise | $63.03 | 5,000 | 315,150 | 12,712 | Nov 03, 2017, 04:41 PM |
| BAUMGARTNER ROBERT V | Director | Nov 01, 2017 | Sale | $130.18 | 5,000 | 650,905 | 7,712 | Nov 03, 2017, 04:41 PM |
| LUCAS ROGER C | Director | Oct 10, 2017 | Sale | $121.96 | 100 | 12,196 | 1,870 | Oct 12, 2017, 04:24 PM |
| LUCAS ROGER C | Director | Sep 08, 2017 | Sale | $120.94 | 100 | 12,094 | 1,970 | Sep 12, 2017, 05:02 PM |
| HOLBROOK KAREN A | Director | Sep 06, 2017 | Sale | $121.73 | 1,059 | 128,909 | 914 | Sep 08, 2017, 04:44 PM |
| LUCAS ROGER C | Director | Aug 10, 2017 | Sale | $114.30 | 100 | 11,430 | 2,070 | Aug 14, 2017, 04:24 PM |
| LUCAS ROGER C | Director | Jul 10, 2017 | Sale | $116.86 | 100 | 11,686 | 2,170 | Jul 12, 2017, 04:34 PM |
| Gould Kevin S | SVP Clinical Controls | Jul 09, 2017 | Option Exercise | $117.68 | 312 | 36,716 | 1,355 | Jul 11, 2017, 05:30 PM |
| Eansor Norman David | SVP - Novus Biologicals | Jul 01, 2017 | Option Exercise | $117.50 | 534 | 62,745 | 3,402 | Jul 05, 2017, 05:46 PM |
| Furlow Brenda S. | Jul 01, 2017 | Option Exercise | $117.50 | 278 | 32,665 | 1,668 | Jul 05, 2017, 12:00 AM | |
| LUCAS ROGER C | Director | Jun 09, 2017 | Sale | $113.62 | 100 | 11,362 | 2,270 | Jun 13, 2017, 04:56 PM |
| LUCAS ROGER C | Director | May 22, 2017 | Sale | $110.01 | 1,059 | 116,505 | 2,370 | Jun 01, 2017, 04:51 PM |
| Dinarello Charles A | Director | May 26, 2017 | Option Exercise | $66.59 | 5,000 | 332,950 | 12,473 | May 31, 2017, 04:58 PM |
| Dinarello Charles A | Director | May 31, 2017 | Sale | $111.37 | 5,000 | 556,860 | 7,473 | May 31, 2017, 04:58 PM |
| HOLBROOK KAREN A | Director | May 25, 2017 | Option Exercise | $66.59 | 5,000 | 332,950 | 6,973 | May 30, 2017, 04:34 PM |
| HOLBROOK KAREN A | Director | May 25, 2017 | Sale | $111.15 | 5,000 | 555,775 | 1,973 | May 30, 2017, 04:34 PM |
| LUCAS ROGER C | Director | May 10, 2017 | Sale | $110.59 | 100 | 11,059 | 3,429 | May 12, 2017, 04:16 PM |
| LUCAS ROGER C | Director | Apr 10, 2017 | Sale | $101.15 | 100 | 10,115 | 3,551 | Apr 12, 2017, 04:52 PM |
| Hippel James | Chief Financial Officer | Mar 31, 2017 | Option Exercise | $101.65 | 800 | 81,320 | 3,079 | Apr 04, 2017, 06:20 PM |
| LUCAS ROGER C | Director | Mar 10, 2017 | Sale | $107.77 | 100 | 10,777 | 3,650 | Mar 14, 2017, 04:43 PM |
| LUCAS ROGER C | Director | Feb 10, 2017 | Sale | $102.60 | 100 | 10,260 | 3,729 | Feb 14, 2017, 05:03 PM |
| LUCAS ROGER C | Director | Jan 10, 2017 | Sale | $103.57 | 100 | 10,357 | 3,829 | Jan 12, 2017, 05:02 PM |
| LUCAS ROGER C | Director | Dec 09, 2016 | Sale | $108.93 | 100 | 10,893 | 3,929 | Dec 13, 2016, 04:31 PM |
| HOLBROOK KAREN A | Director | Nov 29, 2016 | Sale | $106.73 | 1,000 | 106,733 | 1,973 | Dec 01, 2016, 04:30 PM |
| LUCAS ROGER C | Director | Nov 16, 2016 | Sale | $105.75 | 100 | 10,575 | 4,029 | Nov 18, 2016, 04:33 PM |
| LUCAS ROGER C | Director | Oct 19, 2016 | Sale | $104.71 | 100 | 10,471 | 3,215 | Oct 31, 2016, 05:10 PM |
| LUCAS ROGER C | Director | Sep 21, 2016 | Sale | $108.91 | 100 | 10,891 | 3,315 | Sep 23, 2016, 04:40 PM |
| Gould Kevin S | SVP Clinical Controls | Sep 08, 2016 | Sale | $110.50 | 524 | 57,904 | 1,667 | Sep 12, 2016, 05:27 PM |
| HIGGINS JOHN L | Director | Sep 08, 2016 | Sale | $109.83 | 1,700 | 186,716 | 1,359 | Sep 12, 2016, 05:27 PM |
| BAUMGARTNER ROBERT V | Director | Sep 02, 2016 | Option Exercise | $65.47 | 2,613 | 171,073 | 8,672 | Sep 06, 2016, 04:36 PM |
| BAUMGARTNER ROBERT V | Director | Sep 01, 2016 | Option Exercise | $65.90 | 3,854 | 253,964 | 9,913 | Sep 06, 2016, 04:36 PM |
| BAUMGARTNER ROBERT V | Director | Sep 02, 2016 | Sale | $107.15 | 2,613 | 279,986 | 6,059 | Sep 06, 2016, 04:36 PM |
| BAUMGARTNER ROBERT V | Director | Sep 01, 2016 | Sale | $107.18 | 3,854 | 413,052 | 6,059 | Sep 06, 2016, 04:36 PM |
| BAUMGARTNER ROBERT V | Director | Aug 24, 2016 | Option Exercise | $66.59 | 3,533 | 235,262 | 9,592 | Aug 26, 2016, 05:38 PM |
| BAUMGARTNER ROBERT V | Director | Aug 24, 2016 | Sale | $107.10 | 3,533 | 378,377 | 6,059 | Aug 26, 2016, 05:38 PM |
| LUCAS ROGER C | Director | Aug 17, 2016 | Sale | $113.70 | 100 | 11,370 | 3,415 | Aug 19, 2016, 04:58 PM |
| LUCAS ROGER C | Director | Jul 20, 2016 | Sale | $111.03 | 100 | 11,103 | 3,615 | Jul 21, 2016, 11:50 AM |
| Gould Kevin S | SVP Clinical Controls | Jul 09, 2016 | Option Exercise | $115.17 | 309 | 35,588 | 2,191 | Jul 12, 2016, 05:33 PM |
| Furlow Brenda S. | SVP - General Counsel | Jul 01, 2016 | Option Exercise | $112.24 | 277 | 31,090 | 1,946 | Jul 06, 2016, 05:11 PM |
| Eansor Norman David | SVP - Novus Biologicals | Jul 01, 2016 | Option Exercise | $112.24 | 533 | 59,824 | 3,936 | Jul 06, 2016, 05:11 PM |
| LUCAS ROGER C | Director | Jun 15, 2016 | Sale | $112.15 | 100 | 11,215 | 3,715 | Jun 16, 2016, 12:27 PM |
| LUCAS ROGER C | Director | May 18, 2016 | Sale | $102.53 | 100 | 10,253 | 3,815 | May 19, 2016, 03:47 PM |
| Dinarello Charles A | Director | May 09, 2016 | Sale | $101.91 | 5,000 | 509,550 | 6,559 | May 10, 2016, 05:43 PM |
| Dinarello Charles A | Director | May 05, 2016 | Option Exercise | $56.17 | 5,000 | 280,850 | 11,559 | May 09, 2016, 02:14 PM |
| LUCAS ROGER C | Director | May 06, 2016 | Sale | $100.24 | 500 | 50,120 | 3,915 | May 09, 2016, 02:14 PM |
| LUCAS ROGER C | Director | Apr 20, 2016 | Sale | $92.40 | 100 | 9,240 | 4,315 | Apr 22, 2016, 04:06 PM |
| Hippel James | Mar 31, 2016 | Option Exercise | $94.52 | 556 | 52,553 | 5,544 | Apr 04, 2016, 02:57 PM | |
| LUCAS ROGER C | Director | Mar 16, 2016 | Sale | $92.90 | 100 | 9,290 | 4,415 | Mar 18, 2016, 01:03 PM |
| LUCAS ROGER C | Director | Feb 05, 2016 | Option Exercise | $70.35 | 5,000 | 351,750 | 9,515 | Feb 08, 2016, 05:48 PM |
| LUCAS ROGER C | Director | Feb 05, 2016 | Sale | $83.68 | 5,000 | 418,400 | 4,515 | Feb 08, 2016, 05:48 PM |
| LUCAS ROGER C | Director | Aug 17, 2015 | Option Exercise | $66.90 | 5,000 | 334,500 | 8,456 | Aug 19, 2015, 04:35 PM |
| LUCAS ROGER C | Director | Aug 17, 2015 | Sale | $106.02 | 5,000 | 530,110 | 3,456 | Aug 19, 2015, 04:35 PM |
| LUCAS ROGER C | Director | Aug 13, 2015 | Option Exercise | $61.46 | 5,000 | 307,300 | 8,456 | Aug 17, 2015, 04:32 PM |
| LUCAS ROGER C | Director | Aug 13, 2015 | Sale | $106.01 | 5,000 | 530,035 | 3,456 | Aug 17, 2015, 04:32 PM |
| Furlow Brenda S. | SVP - General Counsel | Aug 07, 2015 | Option Exercise | $97.54 | 5,540 | 540,372 | 2,223 | Aug 11, 2015, 04:41 PM |
| Eansor Norman David | SVP Biotech | Jul 02, 2015 | Option Exercise | $96.54 | 531 | 51,263 | 1,136 | Jul 06, 2015, 10:03 AM |
| STEER RANDOLPH C | Director | Jun 08, 2015 | Sale | $99.39 | 1,000 | 99,386 | 1,000 | Jun 09, 2015, 10:33 AM |
| VERONNEAU MARCEL | SVP - Clinical Controls | Jun 08, 2015 | Option Exercise | $98.75 | 309 | 30,514 | 34,604 | Jun 09, 2015, 10:18 AM |
| VERONNEAU MARCEL | SVP - Clinical Controls | Jun 08, 2015 | Option Exercise | $79.41 | 385 | 30,573 | 34,989 | Jun 09, 2015, 10:18 AM |
| Hippel James | Chief Financial Officer | Mar 31, 2015 | Option Exercise | $100.29 | 566 | 56,764 | 1,100 | Apr 02, 2015, 04:32 PM |
| OCONNELL HOWARD V | Director | Feb 19, 2015 | Option Exercise | $56.17 | 5,000 | 280,850 | 75,000 | Feb 20, 2015, 01:38 PM |
| OCONNELL HOWARD V | Director | Feb 19, 2015 | Sale | $95.78 | 5,000 | 478,882 | 70,000 | Feb 20, 2015, 01:38 PM |
| Dinarello Charles A | Director | Feb 05, 2015 | Option Exercise | $54.91 | 1,500 | 82,365 | 5,500 | Feb 06, 2015, 03:40 PM |
| HOLBROOK KAREN A | Director | Dec 10, 2014 | Sale | $92.40 | 1,000 | 92,400 | 1,000 | Dec 12, 2014, 10:42 AM |
| Dinarello Charles A | Director | Dec 08, 2014 | Sale | $90.44 | 3,000 | 271,320 | 4,000 | Dec 10, 2014, 04:57 PM |
| REAGAN KEVIN J | Senior VP - Biotech | Dec 09, 2014 | Option Exercise | $70.96 | 2,591 | 183,857 | 2,591 | Dec 09, 2014, 04:14 PM |
| REAGAN KEVIN J | Senior VP - Biotech | Dec 05, 2014 | Option Exercise | $70.96 | 1,000 | 70,960 | 1,000 | Dec 09, 2014, 04:14 PM |
| REAGAN KEVIN J | Senior VP - Biotech | Dec 05, 2014 | Sale | $89.41 | 1,000 | 89,412 | 0 | Dec 09, 2014, 04:14 PM |
| REAGAN KEVIN J | Senior VP - Biotech | Dec 09, 2014 | Sale | $89.32 | 2,591 | 231,432 | 0 | Dec 09, 2014, 04:14 PM |
| Dinarello Charles A | Director | Sep 09, 2014 | Option Exercise | $54.91 | 5,000 | 274,550 | 6,000 | Sep 10, 2014, 04:29 PM |
| HOLBROOK KAREN A | Director | Aug 14, 2014 | Option Exercise | $57.06 | 5,000 | 285,300 | 6,000 | Aug 15, 2014, 05:19 PM |
| HOLBROOK KAREN A | Director | Aug 14, 2014 | Sale | $95.54 | 5,000 | 477,700 | 1,000 | Aug 15, 2014, 05:19 PM |
| VERONNEAU MARCEL | VP Clinical Controls | Jun 02, 2014 | Option Exercise | $87.34 | 331 | 28,910 | 34,403 | Jun 03, 2014, 11:38 AM |
| VERONNEAU MARCEL | VP Clinical Controls | Jun 02, 2014 | Option Exercise | $56.83 | 510 | 28,983 | 34,913 | Jun 03, 2014, 11:38 AM |
| OCONNELL HOWARD V | Director | May 07, 2014 | Option Exercise | $54.68 | 4,066 | 222,329 | 74,066 | May 08, 2014, 10:17 AM |
| OCONNELL HOWARD V | Director | May 06, 2014 | Option Exercise | $54.68 | 934 | 51,071 | 70,934 | May 08, 2014, 10:17 AM |
| OCONNELL HOWARD V | Director | May 07, 2014 | Sale | $91.00 | 4,066 | 370,006 | 70,000 | May 08, 2014, 10:17 AM |
| OCONNELL HOWARD V | Director | May 06, 2014 | Sale | $91.00 | 934 | 84,994 | 70,000 | May 08, 2014, 10:17 AM |
| HOLBROOK KAREN A | Director | Mar 04, 2014 | Option Exercise | $57.06 | 5,000 | 285,300 | 6,000 | Mar 06, 2014, 11:11 AM |
| HOLBROOK KAREN A | Director | Mar 04, 2014 | Sale | $89.83 | 5,000 | 449,150 | 1,000 | Mar 06, 2014, 11:11 AM |
| STEER RANDOLPH C | Director | Feb 27, 2014 | Option Exercise | $61.46 | 5,000 | 307,300 | 6,000 | Feb 28, 2014, 12:34 PM |
| STEER RANDOLPH C | Director | Feb 27, 2014 | Sale | $88.78 | 5,000 | 443,900 | 1,000 | Feb 28, 2014, 12:34 PM |
| LUCAS ROGER C | Director | Feb 19, 2014 | Option Exercise | $65.03 | 15,000 | 975,450 | 17,456 | Feb 21, 2014, 04:15 PM |
| LUCAS ROGER C | Director | Feb 19, 2014 | Sale | $90.03 | 15,000 | 1,350,507 | 2,456 | Feb 21, 2014, 04:15 PM |
| STEER RANDOLPH C | Director | Nov 13, 2013 | Option Exercise | $65.03 | 15,000 | 975,450 | 16,000 | Nov 15, 2013, 09:37 AM |
| STEER RANDOLPH C | Director | Nov 13, 2013 | Sale | $86.20 | 15,000 | 1,293,000 | 1,000 | Nov 15, 2013, 09:37 AM |
| BAUMGARTNER ROBERT V | Director | Nov 08, 2013 | Option Exercise | $55.42 | 10,000 | 554,250 | 14,000 | Nov 12, 2013, 09:58 AM |
| BAUMGARTNER ROBERT V | Director | Nov 08, 2013 | Sale | $87.00 | 10,000 | 870,000 | 4,000 | Nov 12, 2013, 09:58 AM |
| LUCAS ROGER C | Director | Nov 04, 2013 | Option Exercise | $55.42 | 10,000 | 554,250 | 12,456 | Nov 05, 2013, 05:46 PM |
| LUCAS ROGER C | Director | Nov 04, 2013 | Sale | $87.64 | 10,000 | 876,400 | 2,456 | Nov 05, 2013, 05:46 PM |
| VERONNEAU MARCEL | VP Clinical Controls | Jul 01, 2013 | Option Exercise | $69.69 | 402 | 28,015 | 34,167 | Jul 03, 2013, 12:06 PM |
| VERONNEAU MARCEL | VP Clinical Controls | Jul 01, 2013 | Option Exercise | $49.43 | 567 | 28,027 | 34,734 | Jul 03, 2013, 12:06 PM |
| OCONNELL HOWARD V | Director | May 06, 2013 | Buy | $65.00 | 2,361 | 153,465 | 70,000 | May 07, 2013, 01:03 PM |
| MELSEN GREGORY J | CEO | Dec 18, 2012 | Option Exercise | $49.43 | 1,012 | 50,023 | 1,438 | Dec 19, 2012, 10:38 AM |
| OCONNELL HOWARD V | Director | Oct 27, 2012 | Option Exercise | $71.65 | 20,000 | 1,433,000 | 67,639 | Nov 28, 2012, 11:22 AM |
| OCONNELL HOWARD V | Director | Oct 26, 2012 | Option Exercise | $37.10 | 5,000 | 185,500 | 95,639 | Nov 28, 2012, 11:22 AM |
| OCONNELL HOWARD V | Director | Oct 26, 2012 | Sale | $71.81 | 8,000 | 574,480 | 87,639 | Nov 28, 2012, 11:22 AM |
| VERONNEAU MARCEL | VP Hematology Operations | Aug 14, 2012 | Option Exercise | $51.60 | 475 | 24,510 | 35,044 | Aug 16, 2012, 04:04 PM |
| VERONNEAU MARCEL | VP Hematology Operations | Aug 14, 2012 | Sale | $67.57 | 475 | 32,096 | 34,569 | Aug 16, 2012, 04:04 PM |
| MELSEN GREGORY J | VP Finance and CFO | Jul 31, 2012 | Option Exercise | $51.60 | 426 | 21,982 | 426 | Aug 01, 2012, 09:54 AM |
| OLAND THOMAS E | CEO, President | Nov 30, 2011 | Option Exercise | $67.49 | 2,000 | 134,980 | 1,177,420 | Dec 06, 2011, 12:57 PM |
| OCONNELL HOWARD V | Director | Dec 05, 2011 | Option Exercise | $66.52 | 350 | 23,282 | 90,639 | Dec 05, 2011, 05:26 PM |
| OLAND THOMAS E | CEO, President | Nov 30, 2011 | Option Exercise | $67.49 | 2,000 | 134,980 | 1,177,420 | Nov 30, 2011, 09:53 PM |
| OCONNELL HOWARD V | Director | Nov 29, 2011 | Option Exercise | $65.02 | 30,000 | 1,950,600 | 90,989 | Nov 29, 2011, 04:31 PM |
| BAUMGARTNER ROBERT V | Director | Nov 25, 2011 | Buy | $62.61 | 1,000 | 62,610 | 3,000 | Nov 28, 2011, 10:27 AM |
| VERONNEAU MARCEL | VP Hematology Operations | May 26, 2011 | Option Exercise | $40.47 | 505 | 20,437 | 35,074 | May 31, 2011, 11:23 AM |
| VERONNEAU MARCEL | VP Hematology Operations | May 26, 2011 | Sale | $81.20 | 505 | 41,004 | 34,569 | May 31, 2011, 11:23 AM |
| BAUMGARTNER ROBERT V | Director | May 09, 2011 | Option Exercise | $36.60 | 5,680 | 207,872 | 7,680 | May 09, 2011, 04:23 PM |
| BAUMGARTNER ROBERT V | Director | May 06, 2011 | Option Exercise | $32.90 | 1,885 | 62,017 | 3,885 | May 09, 2011, 04:23 PM |
| BAUMGARTNER ROBERT V | Director | May 09, 2011 | Sale | $78.50 | 5,680 | 445,880 | 2,000 | May 09, 2011, 04:23 PM |
| BAUMGARTNER ROBERT V | Director | May 06, 2011 | Sale | $78.68 | 1,885 | 148,312 | 2,000 | May 09, 2011, 04:23 PM |
| BAUMGARTNER ROBERT V | Director | May 04, 2011 | Option Exercise | $32.90 | 2,435 | 80,112 | 4,435 | May 05, 2011, 12:15 PM |
| BAUMGARTNER ROBERT V | Director | May 04, 2011 | Sale | $78.84 | 2,435 | 191,974 | 2,000 | May 05, 2011, 12:15 PM |
| OCONNELL HOWARD V | Director | May 04, 2011 | Option Exercise | $78.56 | 1,640 | 128,838 | 120,989 | May 05, 2011, 11:53 AM |
| OCONNELL HOWARD V | Director | May 04, 2011 | Option Exercise | $31.78 | 10,000 | 317,750 | 137,629 | May 05, 2011, 11:37 AM |
| OCONNELL HOWARD V | Director | May 04, 2011 | Sale | $79.19 | 15,000 | 1,187,807 | 122,629 | May 05, 2011, 11:37 AM |
| OCONNELL HOWARD V | Director | Dec 08, 2010 | Option Exercise | $29.10 | 3,000 | 87,300 | 130,629 | Dec 09, 2010, 04:58 PM |
| OCONNELL HOWARD V | Director | Dec 08, 2010 | Sale | $61.30 | 3,000 | 183,900 | 127,629 | Dec 09, 2010, 04:58 PM |
| OLAND THOMAS E | CEO, President | Nov 09, 2010 | Option Exercise | $60.22 | 2,000 | 120,440 | 1,179,420 | Nov 10, 2010, 09:12 AM |
| OCONNELL HOWARD V | Director | Nov 03, 2010 | Option Exercise | $52.66 | 10,000 | 526,565 | 137,629 | Nov 04, 2010, 11:35 AM |
| OCONNELL HOWARD V | Director | Nov 03, 2010 | Sale | $61.01 | 10,000 | 610,100 | 127,629 | Nov 04, 2010, 11:35 AM |
| VERONNEAU MARCEL | VP Hematology Operations | Nov 02, 2010 | Option Exercise | $61.31 | 4,520 | 277,121 | 27,080 | Nov 04, 2010, 11:08 AM |
| VERONNEAU MARCEL | VP Hematology Operations | Nov 03, 2010 | Option Exercise | $37.01 | 7,511 | 277,990 | 42,080 | Nov 04, 2010, 11:08 AM |
| VERONNEAU MARCEL | VP Hematology Operations | Nov 02, 2010 | Option Exercise | $37.01 | 7,489 | 277,175 | 34,569 | Nov 04, 2010, 11:08 AM |
| VERONNEAU MARCEL | VP Hematology Operations | Nov 03, 2010 | Sale | $61.08 | 7,511 | 458,772 | 34,569 | Nov 04, 2010, 11:08 AM |
| LUCAS ROGER C | Director | Aug 20, 2010 | Option Exercise | $52.66 | 10,000 | 526,565 | 11,456 | Aug 24, 2010, 09:34 AM |
| LUCAS ROGER C | Director | Aug 20, 2010 | Sale | $60.01 | 10,000 | 600,150 | 1,456 | Aug 24, 2010, 09:34 AM |
| VERONNEAU MARCEL | VP Hematology Operations | Aug 04, 2010 | Option Exercise | $61.44 | 369 | 22,671 | 30,930 | Aug 06, 2010, 10:57 AM |
| VERONNEAU MARCEL | VP Hematology Operations | Aug 04, 2010 | Option Exercise | $33.85 | 670 | 22,679 | 31,600 | Aug 06, 2010, 10:57 AM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Bohnen Shane | SVP - General Counsel | 04/03/2024 | 50,699 |
| Nusse Roeland | Director | 03/07/2024 | 800,627 |
| Geist William | PRESIDENT, PROTEIN SCIENCES | 02/01/2024 | 76,148 |
| Hippel James | CFO | 12/19/2023 | 2,552,228 |
| Hippel James | CFO | 12/19/2023 | 1,478,254 |
| Nusse Roeland | Director | 08/30/2023 | 716,800 |
| Nusse Roeland | Director | 08/30/2023 | 717,959 |
| Kelderman Kim | Pres. Diagnostics & Genom | 08/24/2023 | 99,960 |
| Kummeth Charles R. | Chief Executive Officer | 08/15/2023 | 733,992 |
| Kummeth Charles R. | Chief Executive Officer | 08/05/2023 | 2,626,317 |
| Hippel James | CFO | 08/05/2023 | 520,547 |
| Kelderman Kim | Pres. Diagnostics & Genom | 08/05/2023 | 340,102 |
| Kummeth Charles R. | Chief Executive Officer | 07/21/2023 | 7,069,024 |
| Kummeth Charles R. | Chief Executive Officer | 06/30/2023 | 31,895,044 |
| Kummeth Charles R. | Chief Executive Officer | 06/30/2023 | 16,434,415 |
| Kummeth Charles R. | Chief Executive Officer | 06/07/2023 | 26,726 |
| HIGGINS JOHN L | Director | 04/28/2023 | 349,635 |
| HIGGINS JOHN L | Director | 04/28/2023 | 349,600 |
| Kummeth Charles R. | Chief Executive Officer | 01/04/2023 | 21,590,084 |
| Kummeth Charles R. | Chief Executive Officer | 01/04/2023 | 10,856,250 |
| Furlow Brenda S. | SVP - GENERAL COUNSEL | 12/08/2022 | 232,906 |
| Furlow Brenda S. | SVP - GENERAL COUNSEL | 12/07/2022 | 25,010 |
| Furlow Brenda S. | SVP - GENERAL COUNSEL | 12/07/2022 | 65,605 |
| Furlow Brenda S. | SVP - GENERAL COUNSEL | 12/08/2022 | 611,810 |
| Kelderman Kim | Pres. Diagnostics & Genom | 08/23/2022 | 99,967 |
| HIGGINS JOHN L | Director | 08/10/2022 | 227,460 |
| HIGGINS JOHN L | Director | 08/11/2022 | 197,322 |
| HIGGINS JOHN L | Director | 08/10/2022 | 751,194 |
| Furlow Brenda S. | SVP - General Counsel | 08/08/2022 | 99,831 |
| Kelderman Kim | Pres. Diagnostics & Genom | 08/07/2022 | 464,926 |
| Furlow Brenda S. | SVP - General Counsel | 08/07/2022 | 371,098 |
| Kummeth Charles R. | Chief Executive Officer | 08/07/2022 | 4,425,984 |
| Hippel James | Chief Financial Officer | 08/07/2022 | 742,196 |
| Kummeth Charles R. | CHIEF EXECUTIVE OFFICER | 07/28/2022 | 10,549,718 |
| Kummeth Charles R. | CHIEF EXECUTIVE OFFICER | 07/28/2022 | 4,919,587 |
| Kummeth Charles R. | CHIEF EXECUTIVE OFFICER | 07/06/2022 | 11,222,599 |
| Kummeth Charles R. | CHIEF EXECUTIVE OFFICER | 07/06/2022 | 5,424,500 |
| HIGGINS JOHN L | Director | 06/08/2022 | 40,140 |
| HIGGINS JOHN L | Director | 06/07/2022 | 66,900 |
| HIGGINS JOHN L | Director | 06/08/2022 | 219,654 |
| HIGGINS JOHN L | Director | 06/07/2022 | 364,310 |
| Kummeth Charles R. | CHIEF EXECUTIVE OFFICER | 06/07/2022 | 553,733 |
| Kummeth Charles R. | CHIEF EXECUTIVE OFFICER | 06/07/2022 | 1,862,960 |
| BAUMGARTNER ROBERT V | Director | 05/10/2022 | 105,765 |
| Kelderman Kim | Pres. Diagnostics & Genom | 02/08/2022 | 299,901 |
| Kummeth Charles R. | Chief Executive Officer | 01/28/2022 | 199,896 |
| Kelderman Kim | Pres. Diagnostics & Genom | 11/19/2021 | 75,390 |
| Kelderman Kim | Pres. Diagnostics & Genom | 11/19/2021 | 252,689 |
| Eansor Norman David | President-Protein Sciences | 11/16/2021 | 99,915 |
| Eansor Norman David | President-Protein Sciences | 11/12/2021 | 3,396,233 |
| Eansor Norman David | President-Protein Sciences | 11/12/2021 | 13,688,196 |
| Hippel James | Chief Financial Officer | 11/01/2021 | 1,103,191 |
| Hippel James | Chief Financial Officer | 11/02/2021 | 25,010 |
| Hippel James | Chief Financial Officer | 11/02/2021 | 105,020 |
| Hippel James | Chief Financial Officer | 11/01/2021 | 4,644,968 |
| Hippel James | Chief Financial Officer | 10/29/2021 | 82,783 |
| Hippel James | Chief Financial Officer | 10/29/2021 | 347,704 |
| Hippel James | Chief Financial Officer | 10/28/2021 | 52,518 |
| Kelderman Kim | Pres. Diagnostics & Genom | 09/22/2021 | 434,871 |
| STEER RANDOLPH C | Director | 09/07/2021 | 716,680 |
| STEER RANDOLPH C | Director | 09/07/2021 | 4,079,824 |
| Kummeth Charles R. | Chief Executive Officer | 09/02/2021 | 21,455,314 |
| Kummeth Charles R. | Chief Executive Officer | 09/02/2021 | 7,973,147 |
| Hippel James | Chief Financial Officer | 09/02/2021 | 1,065,900 |
| Hippel James | Chief Financial Officer | 09/02/2021 | 5,072,164 |
| Furlow Brenda S. | SVP - General Counsel | 09/02/2021 | 859,219 |
| Furlow Brenda S. | SVP - General Counsel | 09/02/2021 | 3,503,767 |
| Eansor Norman David | President-Protein Sciences | 08/31/2021 | 773,728 |
| Furlow Brenda S. | SVP - General Counsel | 08/31/2021 | 625,250 |
| Furlow Brenda S. | SVP - General Counsel | 08/31/2021 | 2,528,312 |
| Nusse Roeland | Director | 08/23/2021 | 281,400 |
| Nusse Roeland | Director | 08/23/2021 | 1,926,064 |
| BAUMGARTNER ROBERT V | Director | 08/23/2021 | 349,560 |
| BAUMGARTNER ROBERT V | Director | 08/23/2021 | 1,942,184 |
| Furlow Brenda S. | SVP - General Counsel | 08/19/2021 | 477,030 |
| Furlow Brenda S. | SVP - General Counsel | 08/19/2021 | 1,676,850 |
| Kummeth Charles R. | Chief Executive Officer | 08/11/2021 | 99,919 |
| Kummeth Charles R. | Chief Executive Officer | 08/06/2021 | 6,010,705 |
| Hippel James | Chief Financial Officer | 08/08/2021 | 802,230 |
| Hippel James | Chief Financial Officer | 08/09/2021 | 1,065,900 |
| Hippel James | Chief Financial Officer | 08/09/2021 | 4,788,994 |
| Kelderman Kim | Pres. Diagnostics & Genom | 08/08/2021 | 418,702 |
| Furlow Brenda S. | SVP - General Counsel | 08/08/2021 | 326,192 |
| Eansor Norman David | President-Protein Sciences | 08/08/2021 | 481,338 |
| Hippel James | Chief Financial Officer | 07/12/2021 | 1,065,900 |
| Hippel James | Chief Financial Officer | 07/12/2021 | 4,566,663 |
| Kelderman Kim | Pres. Diagnostics & Genom | 05/01/2021 | 365,931 |
| Kummeth Charles R. | Chief Executive Officer | 02/16/2021 | 7,162,908 |
| Kummeth Charles R. | Chief Executive Officer | 02/16/2021 | 2,830,500 |
| Hippel James | Chief Financial Officer | 02/12/2021 | 1,065,900 |
| Hippel James | Chief Financial Officer | 02/12/2021 | 4,003,909 |
| Furlow Brenda S. | SVP - General Counsel | 02/12/2021 | 1,065,900 |
| Furlow Brenda S. | SVP - General Counsel | 02/12/2021 | 3,986,348 |
| Nusse Roeland | Director | 02/08/2021 | 404,850 |
| Nusse Roeland | Director | 02/08/2021 | 2,310,480 |
| Kelderman Kim | Pres. Diagnostics & Genom | 02/05/2021 | 319,694 |
| Eansor Norman David | President-Protein Sciences | 02/05/2021 | 3,510,328 |
| Eansor Norman David | President-Protein Sciences | 02/05/2021 | 12,537,024 |
| Kummeth Charles R. | Chief Executive Officer | 01/15/2021 | 6,880,000 |
| Hippel James | Chief Financial Officer | 01/11/2021 | 1,065,900 |
| Hippel James | Chief Financial Officer | 01/11/2021 | 3,336,323 |
| Kummeth Charles R. | Chief Executive Officer | 12/07/2020 | 1,540,000 |
| Furlow Brenda S. | SVP - General Counsel | 11/30/2020 | 1,257,229 |
| Furlow Brenda S. | SVP - General Counsel | 11/30/2020 | 3,278,128 |
| BAUMGARTNER ROBERT V | Director | 11/18/2020 | 334,500 |
| BAUMGARTNER ROBERT V | Director | 11/18/2020 | 1,516,675 |
| Seth Alpna | Director | 11/09/2020 | 732,118 |
| Seth Alpna | Director | 11/09/2020 | 1,540,167 |
| Hippel James | Chief Financial Officer | 11/11/2020 | 787,807 |
| Hippel James | Chief Financial Officer | 11/09/2020 | 383,724 |
| Hippel James | Chief Financial Officer | 11/11/2020 | 2,269,426 |
| Hippel James | Chief Financial Officer | 11/09/2020 | 1,115,252 |
| Kummeth Charles R. | Chief Executive Officer | 11/06/2020 | 4,650,476 |
| Kummeth Charles R. | Chief Executive Officer | 11/06/2020 | 2,169,791 |
| STEER RANDOLPH C | Director | 11/06/2020 | 686,250 |
| STEER RANDOLPH C | Director | 11/06/2020 | 3,019,948 |
| HIGGINS JOHN L | Director | 11/06/2020 | 351,750 |
| HIGGINS JOHN L | Director | 11/06/2020 | 1,501,746 |
| Hippel James | Chief Financial Officer | 11/05/2020 | 955,688 |
| Hippel James | Chief Financial Officer | 11/04/2020 | 770,279 |
| Hippel James | Chief Financial Officer | 11/04/2020 | 1,945,426 |
| Hippel James | Chief Financial Officer | 11/05/2020 | 2,520,454 |
| Furlow Brenda S. | SVP - General Counsel | 08/09/2020 | 225,630 |
| Eansor Norman David | President-Protein Sciences | 08/09/2020 | 227,491 |
| Hippel James | Chief Financial Officer | 08/09/2020 | 580,420 |
| Kummeth Charles R. | Chief Executive Officer | 08/09/2020 | 3,265,393 |
| Furlow Brenda S. | SVP - General Counsel | 07/09/2020 | 984,981 |
| Furlow Brenda S. | SVP - General Counsel | 07/09/2020 | 2,503,654 |
| Hippel James | Chief Financial Officer | 07/07/2020 | 279,579 |
| Hippel James | Chief Financial Officer | 07/06/2020 | 2,332,752 |
| Hippel James | Chief Financial Officer | 07/07/2020 | 699,482 |
| Hippel James | Chief Financial Officer | 07/06/2020 | 5,840,148 |
| WIENS HAROLD J | Director | 05/29/2020 | 403,242 |
| WIENS HAROLD J | Director | 05/29/2020 | 1,036,100 |
| Furlow Brenda S. | SVP - General Counsel | 05/28/2020 | 801,358 |
| Furlow Brenda S. | SVP - General Counsel | 05/28/2020 | 1,559,534 |
| Eansor Norman David | President-Protein Sciences | 05/29/2020 | 858,047 |
| Eansor Norman David | President-Protein Sciences | 05/28/2020 | 374,074 |
| Eansor Norman David | President-Protein Sciences | 05/29/2020 | 2,072,140 |
| Eansor Norman David | President-Protein Sciences | 05/28/2020 | 897,135 |
| Kummeth Charles R. | Chief Executive Officer | 05/26/2020 | 3,467,995 |
| Kummeth Charles R. | Chief Executive Officer | 05/26/2020 | 1,824,964 |
| Eansor Norman David | President-Protein Sciences | 05/22/2020 | 1,310,937 |
| Eansor Norman David | President-Protein Sciences | 05/21/2020 | 1,041,341 |
| Eansor Norman David | President-Protein Sciences | 05/22/2020 | 3,375,926 |
| Eansor Norman David | President-Protein Sciences | 05/21/2020 | 2,952,316 |
| BAUMGARTNER ROBERT V | Director | 05/21/2020 | 351,750 |
| BAUMGARTNER ROBERT V | Director | 05/21/2020 | 1,332,118 |
| WIENS HAROLD J | Director | 05/06/2020 | 372,068 |
| WIENS HAROLD J | Director | 05/06/2020 | 1,065,000 |
| Kelderman Kim | Pres. Diagnostics & Genom | 05/01/2020 | 186,810 |
| WIENS HAROLD J | Director | 04/30/2020 | 367,120 |
| WIENS HAROLD J | Director | 04/30/2020 | 900,000 |
| Eansor Norman David | President-Protein Sciences | 03/04/2020 | 275,569 |
| HIGGINS JOHN L | Director | 02/12/2020 | 307,300 |
| HIGGINS JOHN L | Director | 02/12/2020 | 1,026,135 |
| Kummeth Charles R. | Chief Executive Officer | 01/06/2020 | 693,219 |
| Kummeth Charles R. | Chief Executive Officer | 01/06/2020 | 2,232,769 |
| Kummeth Charles R. | Chief Executive Officer | 01/03/2020 | 539,613 |
| Kummeth Charles R. | Chief Executive Officer | 01/02/2020 | 1,338,609 |
| Kummeth Charles R. | Chief Executive Officer | 01/03/2020 | 1,740,240 |
| Kummeth Charles R. | Chief Executive Officer | 01/02/2020 | 4,337,541 |
| Kummeth Charles R. | Chief Executive Officer | 12/23/2019 | 44,456 |
| Kummeth Charles R. | Chief Executive Officer | 12/24/2019 | 31,774 |
| Kummeth Charles R. | Chief Executive Officer | 12/23/2019 | 146,351 |
| Kummeth Charles R. | Chief Executive Officer | 12/24/2019 | 104,648 |
| Kummeth Charles R. | Chief Executive Officer | 12/20/2019 | 389,042 |
| Kummeth Charles R. | Chief Executive Officer | 12/20/2019 | 1,280,632 |
| Kummeth Charles R. | Chief Executive Officer | 12/20/2019 | 389,042 |
| Kummeth Charles R. | Chief Executive Officer | 12/20/2019 | 1,280,632 |
| Furlow Brenda S. | SVP - General Counsel | 12/12/2019 | 754,800 |
| Furlow Brenda S. | SVP - General Counsel | 12/12/2019 | 1,724,773 |
| Kummeth Charles R. | Chief Executive Officer | 12/10/2019 | 47,424 |
| Kummeth Charles R. | Chief Executive Officer | 12/10/2019 | 156,073 |
| WIENS HAROLD J | Director | 12/04/2019 | 175,660 |
| WIENS HAROLD J | Director | 12/04/2019 | 435,693 |
| Kummeth Charles R. | Chief Executive Officer | 11/27/2019 | 794,139 |
| Kummeth Charles R. | Chief Executive Officer | 11/27/2019 | 2,614,820 |
| Kummeth Charles R. | Chief Executive Officer | 11/29/2019 | 22,262 |
| Nusse Roeland | Director | 11/25/2019 | 911,900 |
| Nusse Roeland | Director | 11/25/2019 | 1,830,731 |
| Hippel James | Chief Financial Officer | 11/21/2019 | 1,070,778 |
| Hippel James | Chief Financial Officer | 11/22/2019 | 2,231,472 |
| Hippel James | Chief Financial Officer | 11/22/2019 | 5,098,899 |
| Hippel James | Chief Financial Officer | 11/21/2019 | 2,444,132 |
| Kummeth Charles R. | Chief Executive Officer | 09/09/2019 | 18,500 |
| Kummeth Charles R. | Chief Executive Officer | 09/09/2019 | 18,500 |
| Eansor Norman David | SVP - Novus Biologicals | 08/19/2019 | 177,813 |
| Hippel James | Chief Financial Officer | 08/19/2019 | 478,910 |
| Furlow Brenda S. | SVP - General Counsel | 08/19/2019 | 147,190 |
| Kummeth Charles R. | Chief Executive Officer | 08/13/2019 | 499,879 |
| BAUMGARTNER ROBERT V | Director | 08/07/2019 | 95,530 |
| Kummeth Charles R. | Chief Executive Officer | 07/10/2019 | 1,144,729 |
| Kummeth Charles R. | Chief Executive Officer | 07/10/2019 | 3,616,427 |
| Kummeth Charles R. | Chief Executive Officer | 07/08/2019 | 1,213,875 |
| Kummeth Charles R. | Chief Executive Officer | 07/09/2019 | 1,014,396 |
| Kummeth Charles R. | Chief Executive Officer | 07/08/2019 | 3,828,188 |
| Kummeth Charles R. | Chief Executive Officer | 07/09/2019 | 3,194,340 |
| Eansor Norman David | SVP - Novus Biologicals | 06/12/2019 | 670,155 |
| HIGGINS JOHN L | Director | 06/04/2019 | 315,150 |
| HIGGINS JOHN L | Director | 06/04/2019 | 1,018,345 |
| Furlow Brenda S. | SVP - General Counsel | 05/24/2019 | 1,080,000 |
| Kelderman Kim | President, Diagnostics & Genom | 05/01/2019 | 170,598 |
| Kelderman Kim | President, Diagnostics & Genom | 05/01/2019 | 336,951 |
| Hippel James | Chief Financial Officer | 05/01/2019 | 3,018,750 |
| Hippel James | Chief Financial Officer | 05/01/2019 | 7,107,695 |
| Kummeth Charles R. | Chief Executive Officer | 08/18/2018 | 241,509 |
| BAUMGARTNER ROBERT V | Director | 08/24/2018 | 307,300 |
| BAUMGARTNER ROBERT V | Director | 08/24/2018 | 942,335 |
| HIGGINS JOHN L | Director | 08/23/2018 | 610,800 |
| HIGGINS JOHN L | Director | 08/23/2018 | 1,879,170 |
| Dinarello Charles A | Director | 08/08/2018 | 315,150 |
| Dinarello Charles A | Director | 08/08/2018 | 884,675 |
| Kummeth Charles R. | Chief Executive Officer | 08/07/2018 | 1,450,667 |
| Eansor Norman David | SVP - Novus Biologicals | 08/07/2018 | 62,689 |
| Furlow Brenda S. | SVP - General Counsel | 08/07/2018 | 78,901 |
| Hippel James | Chief Financial Officer | 08/07/2018 | 197,073 |
| Kummeth Charles R. | Chief Executive Officer | 06/07/2018 | 1,280,000 |
| Eansor Norman David | SVP - Novus Biologicals | 05/04/2018 | 164,931 |
| Dinarello Charles A | Director | 02/13/2018 | 327,350 |
| Dinarello Charles A | Director | 02/13/2018 | 680,303 |
| BAUMGARTNER ROBERT V | Director | 11/01/2017 | 315,150 |
| BAUMGARTNER ROBERT V | Director | 11/01/2017 | 650,905 |
| LUCAS ROGER C | Director | 10/10/2017 | 12,196 |
| LUCAS ROGER C | Director | 09/08/2017 | 12,094 |
| HOLBROOK KAREN A | Director | 09/06/2017 | 128,909 |
| LUCAS ROGER C | Director | 08/10/2017 | 11,430 |
| LUCAS ROGER C | Director | 07/10/2017 | 11,686 |
| Gould Kevin S | SVP Clinical Controls | 07/09/2017 | 36,716 |
| Eansor Norman David | SVP - Novus Biologicals | 07/01/2017 | 62,745 |
| Furlow Brenda S. | 07/01/2017 | 32,665 | |
| LUCAS ROGER C | Director | 06/09/2017 | 11,362 |
| LUCAS ROGER C | Director | 05/22/2017 | 116,505 |
| Dinarello Charles A | Director | 05/26/2017 | 332,950 |
| Dinarello Charles A | Director | 05/31/2017 | 556,860 |
| HOLBROOK KAREN A | Director | 05/25/2017 | 332,950 |
| HOLBROOK KAREN A | Director | 05/25/2017 | 555,775 |
| LUCAS ROGER C | Director | 05/10/2017 | 11,059 |
| LUCAS ROGER C | Director | 04/10/2017 | 10,115 |
| Hippel James | Chief Financial Officer | 03/31/2017 | 81,320 |
| LUCAS ROGER C | Director | 03/10/2017 | 10,777 |
| LUCAS ROGER C | Director | 02/10/2017 | 10,260 |
| LUCAS ROGER C | Director | 01/10/2017 | 10,357 |
| LUCAS ROGER C | Director | 12/09/2016 | 10,893 |
| HOLBROOK KAREN A | Director | 11/29/2016 | 106,733 |
| LUCAS ROGER C | Director | 11/16/2016 | 10,575 |
| LUCAS ROGER C | Director | 10/19/2016 | 10,471 |
| LUCAS ROGER C | Director | 09/21/2016 | 10,891 |
| Gould Kevin S | SVP Clinical Controls | 09/08/2016 | 57,904 |
| HIGGINS JOHN L | Director | 09/08/2016 | 186,716 |
| BAUMGARTNER ROBERT V | Director | 09/02/2016 | 171,073 |
| BAUMGARTNER ROBERT V | Director | 09/01/2016 | 253,964 |
| BAUMGARTNER ROBERT V | Director | 09/02/2016 | 279,986 |
| BAUMGARTNER ROBERT V | Director | 09/01/2016 | 413,052 |
| BAUMGARTNER ROBERT V | Director | 08/24/2016 | 235,262 |
| BAUMGARTNER ROBERT V | Director | 08/24/2016 | 378,377 |
| LUCAS ROGER C | Director | 08/17/2016 | 11,370 |
| LUCAS ROGER C | Director | 07/20/2016 | 11,103 |
| Gould Kevin S | SVP Clinical Controls | 07/09/2016 | 35,588 |
| Furlow Brenda S. | SVP - General Counsel | 07/01/2016 | 31,090 |
| Eansor Norman David | SVP - Novus Biologicals | 07/01/2016 | 59,824 |
| LUCAS ROGER C | Director | 06/15/2016 | 11,215 |
| LUCAS ROGER C | Director | 05/18/2016 | 10,253 |
| Dinarello Charles A | Director | 05/09/2016 | 509,550 |
| Dinarello Charles A | Director | 05/05/2016 | 280,850 |
| LUCAS ROGER C | Director | 05/06/2016 | 50,120 |
| LUCAS ROGER C | Director | 04/20/2016 | 9,240 |
| Hippel James | 03/31/2016 | 52,553 | |
| LUCAS ROGER C | Director | 03/16/2016 | 9,290 |
| LUCAS ROGER C | Director | 02/05/2016 | 351,750 |
| LUCAS ROGER C | Director | 02/05/2016 | 418,400 |
| LUCAS ROGER C | Director | 08/17/2015 | 334,500 |
| LUCAS ROGER C | Director | 08/17/2015 | 530,110 |
| LUCAS ROGER C | Director | 08/13/2015 | 307,300 |
| LUCAS ROGER C | Director | 08/13/2015 | 530,035 |
| Furlow Brenda S. | SVP - General Counsel | 08/07/2015 | 540,372 |
| Eansor Norman David | SVP Biotech | 07/02/2015 | 51,263 |
| STEER RANDOLPH C | Director | 06/08/2015 | 99,386 |
| VERONNEAU MARCEL | SVP - Clinical Controls | 06/08/2015 | 30,514 |
| VERONNEAU MARCEL | SVP - Clinical Controls | 06/08/2015 | 30,573 |
| Hippel James | Chief Financial Officer | 03/31/2015 | 56,764 |
| OCONNELL HOWARD V | Director | 02/19/2015 | 280,850 |
| OCONNELL HOWARD V | Director | 02/19/2015 | 478,882 |
| Dinarello Charles A | Director | 02/05/2015 | 82,365 |
| HOLBROOK KAREN A | Director | 12/10/2014 | 92,400 |
| Dinarello Charles A | Director | 12/08/2014 | 271,320 |
| REAGAN KEVIN J | Senior VP - Biotech | 12/09/2014 | 183,857 |
| REAGAN KEVIN J | Senior VP - Biotech | 12/05/2014 | 70,960 |
| REAGAN KEVIN J | Senior VP - Biotech | 12/05/2014 | 89,412 |
| REAGAN KEVIN J | Senior VP - Biotech | 12/09/2014 | 231,432 |
| Dinarello Charles A | Director | 09/09/2014 | 274,550 |
| HOLBROOK KAREN A | Director | 08/14/2014 | 285,300 |
| HOLBROOK KAREN A | Director | 08/14/2014 | 477,700 |
| VERONNEAU MARCEL | VP Clinical Controls | 06/02/2014 | 28,910 |
| VERONNEAU MARCEL | VP Clinical Controls | 06/02/2014 | 28,983 |
| OCONNELL HOWARD V | Director | 05/07/2014 | 222,329 |
| OCONNELL HOWARD V | Director | 05/06/2014 | 51,071 |
| OCONNELL HOWARD V | Director | 05/07/2014 | 370,006 |
| OCONNELL HOWARD V | Director | 05/06/2014 | 84,994 |
| HOLBROOK KAREN A | Director | 03/04/2014 | 285,300 |
| HOLBROOK KAREN A | Director | 03/04/2014 | 449,150 |
| STEER RANDOLPH C | Director | 02/27/2014 | 307,300 |
| STEER RANDOLPH C | Director | 02/27/2014 | 443,900 |
| LUCAS ROGER C | Director | 02/19/2014 | 975,450 |
| LUCAS ROGER C | Director | 02/19/2014 | 1,350,507 |
| STEER RANDOLPH C | Director | 11/13/2013 | 975,450 |
| STEER RANDOLPH C | Director | 11/13/2013 | 1,293,000 |
| BAUMGARTNER ROBERT V | Director | 11/08/2013 | 554,250 |
| BAUMGARTNER ROBERT V | Director | 11/08/2013 | 870,000 |
| LUCAS ROGER C | Director | 11/04/2013 | 554,250 |
| LUCAS ROGER C | Director | 11/04/2013 | 876,400 |
| VERONNEAU MARCEL | VP Clinical Controls | 07/01/2013 | 28,015 |
| VERONNEAU MARCEL | VP Clinical Controls | 07/01/2013 | 28,027 |
| OCONNELL HOWARD V | Director | 05/06/2013 | 153,465 |
| MELSEN GREGORY J | CEO | 12/18/2012 | 50,023 |
| OCONNELL HOWARD V | Director | 10/27/2012 | 1,433,000 |
| OCONNELL HOWARD V | Director | 10/26/2012 | 185,500 |
| OCONNELL HOWARD V | Director | 10/26/2012 | 574,480 |
| VERONNEAU MARCEL | VP Hematology Operations | 08/14/2012 | 24,510 |
| VERONNEAU MARCEL | VP Hematology Operations | 08/14/2012 | 32,096 |
| MELSEN GREGORY J | VP Finance and CFO | 07/31/2012 | 21,982 |
| OLAND THOMAS E | CEO, President | 11/30/2011 | 134,980 |
| OCONNELL HOWARD V | Director | 12/05/2011 | 23,282 |
| OLAND THOMAS E | CEO, President | 11/30/2011 | 134,980 |
| OCONNELL HOWARD V | Director | 11/29/2011 | 1,950,600 |
| BAUMGARTNER ROBERT V | Director | 11/25/2011 | 62,610 |
| VERONNEAU MARCEL | VP Hematology Operations | 05/26/2011 | 20,437 |
| VERONNEAU MARCEL | VP Hematology Operations | 05/26/2011 | 41,004 |
| BAUMGARTNER ROBERT V | Director | 05/09/2011 | 207,872 |
| BAUMGARTNER ROBERT V | Director | 05/06/2011 | 62,017 |
| BAUMGARTNER ROBERT V | Director | 05/09/2011 | 445,880 |
| BAUMGARTNER ROBERT V | Director | 05/06/2011 | 148,312 |
| BAUMGARTNER ROBERT V | Director | 05/04/2011 | 80,112 |
| BAUMGARTNER ROBERT V | Director | 05/04/2011 | 191,974 |
| OCONNELL HOWARD V | Director | 05/04/2011 | 128,838 |
| OCONNELL HOWARD V | Director | 05/04/2011 | 317,750 |
| OCONNELL HOWARD V | Director | 05/04/2011 | 1,187,807 |
| OCONNELL HOWARD V | Director | 12/08/2010 | 87,300 |
| OCONNELL HOWARD V | Director | 12/08/2010 | 183,900 |
| OLAND THOMAS E | CEO, President | 11/09/2010 | 120,440 |
| OCONNELL HOWARD V | Director | 11/03/2010 | 526,565 |
| OCONNELL HOWARD V | Director | 11/03/2010 | 610,100 |
| VERONNEAU MARCEL | VP Hematology Operations | 11/02/2010 | 277,121 |
| VERONNEAU MARCEL | VP Hematology Operations | 11/03/2010 | 277,990 |
| VERONNEAU MARCEL | VP Hematology Operations | 11/02/2010 | 277,175 |
| VERONNEAU MARCEL | VP Hematology Operations | 11/03/2010 | 458,772 |
| LUCAS ROGER C | Director | 08/20/2010 | 526,565 |
| LUCAS ROGER C | Director | 08/20/2010 | 600,150 |
| VERONNEAU MARCEL | VP Hematology Operations | 08/04/2010 | 22,671 |
| VERONNEAU MARCEL | VP Hematology Operations | 08/04/2010 | 22,679 |
Load More Insider Transactions
FUNDS WITH A POSITION IN BIO-TECHNE CORP
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 18,133,912 | 0.04% | -0.8% | Other |
| BAMCO INC /NY/ | 5,352,006 | 1.1% | -0.45% | Growth At A Reasonable Price |
| SELECT EQUITY GROUP, L.P. | 4,559,173 | 1.25% | -6.5% | Growth At A Reasonable Price |
| GEODE CAPITAL MANAGEMENT, LLC | 3,721,727 | 0.03% | 2.85% | Other |
| ROYCE & ASSOCIATES LP | 683,470 | 0.49% | 1.36% | Value |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 353,600 | 0.06% | 125.94% | Other |
| AQR CAPITAL MANAGEMENT LLC | 60,361 | 0.00877% | 45.05% | Other |
| POLEN CAPITAL MANAGEMENT LLC | 22,383 | 0.00416% | New | Growth At A Reasonable Price, Growth |
| ASHFORD CAPITAL MANAGEMENT INC | 18,160 | 0.19% | No change | Growth |
| WCM INVESTMENT MANAGEMENT, LLC | 13,029 | 0.00282% | New | Growth At A Reasonable Price |
| SANDS CAPITAL MANAGEMENT, LLC | 12,554 | 0.00294% | 31.73% | Growth At A Reasonable Price, Growth |
| BRIDGEWATER ASSOCIATES, LP | 7,302 | 0.00315% | -40.72% | Other |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,600 | 0.00907% | New | Growth At A Reasonable Price |
CHANGE IN SHARES OUTSTANDING FOR BIO-TECHNE CORP
STOCK BUYBACKS FOR BIO-TECHNE CORP
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
-1.16%
1Q
06/30/2023
-1.27%
2Q
03/31/2023
-0.96%
3Q
12/31/2022
-1.04%
4Q
09/30/2022
-1.30%
5Q
06/30/2022
-2.15%
6Q
03/31/2022
-2.33%
7Q
12/31/2021
-2.89%
8Q
09/30/2021
-2.78%
9Q
06/30/2021
-2.44%
10Q
03/31/2021
-1.63%
11Q
12/31/2020
-0.60%
12Q
09/30/2020
-0.02%
13Q
06/30/2020
1.20%
14Q
03/31/2020
1.47%
15Q
12/31/2019
1.18%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR BIO-TECHNE CORP
LOADING...